Nevro has appointed Michael DeMane as president and chief executive officer (CEO) effective immediately.

DeMane will also join the company’s Board of Directors.

DeMane is a veteran medical device company executive, having held leadership roles in the US, Europe and Australia over the past 30 years.

DeMane’s recent operating role was COO of Medtronic (MDT) and prior to that he served as Medtronic’s senior vice president and president Europe, Canada, Latin America and Emerging Markets directing the company’s operations in those regions.

Nevro has developed a novel therapy for spinal cord stimulation (SCS) for the treatment of chronic back and leg pain based on intellectual property licensed from the Mayo Clinic.

The neuromodulation technology is designed to provide pain relief without side effects such as paresthesia and movement induced jolting and the SCS system is approved for commercial use in Europe.

DeMane succeeds company founder and CEO Konstantinos Alataris, who will remain with the company and continue as a Director of the company.